ADMETatlas — Peptide ADMET Evidence Atlas

Evidence entries

125records·47peptides

Showing reference-linked Plasma protein binding evidence with reported value, assay context, interpretation role, and reference access kept separate.

Assay context

Evidence role

All125 Curated comparable98 Reported27

#	Endpoint	Peptide		Assay context	Evidence role	Reference
1	Plasma protein binding Distribution / Barrier	ATLPC0027686	79-83 %	Health Canada SBD 3.3.2 pharmacokinetics manual extractionserumhumanlanreotide 12-60 ng/mL	Comparable	Open
2	Plasma protein binding Distribution / Barrier	ATLPC0015943	~ 15 %	UK eMC SmPC section 5.2 pharmacokinetics manual extractionserumhuman	Comparable	Open
3	Plasma protein binding Distribution / Barrier	ATLPC0004440	Observation plasma protein binding not determined due to hydrolysis of vosoritide in human plasma	FDA Integrated Review Table 5 manual extractionplasmahuman	Reported	Open
4	Plasma protein binding Distribution / Barrier	ATLPC0007210	44 %	New Zealand Medsafe Data Sheet section 5.2 pharmacokinetics manual extractionplasmahumannot route-specificFIRAZYR pharmacokinetic profile characterized using intravenous and subcutaneous administration	Comparable	Open
5	Plasma protein binding Distribution / Barrier	ATLPC0001542	30-40 %	Australian Medicine Finder PI 5.2 pharmacokinetics manual extractionplasmahuman	Comparable	Open
6	Plasma protein binding Distribution / Barrier	ATLPC0024280	> 98 %	PepTherDia curated product PK fieldplasma proteinSC	Reported	Open
7	Plasma protein binding Distribution / Barrier	ATLPC0023266	Observation Pramlintide does not extensively bind to blood cells or albumin (approximately 40% of the drug is unbound in plasma).	PepTherDia curated product PK fieldplasma proteinSC	Reported	Open
8	Plasma protein binding Distribution / Barrier	ATLPC0009237	Observation Not determined	PepTherDia curated product PK fieldplasma proteinSC	Reported	Open
9	Plasma protein binding Distribution / Barrier	ATLPC0025642	65 %	PepTherDia curated product PK fieldplasma proteinSC, IV, IM	Comparable	Open
10	Plasma protein binding Distribution / Barrier	ATLPC0019799	70 %	PepTherDia curated product PK fieldplasma proteinSC	Comparable	Open
11	Plasma protein binding Distribution / Barrier	ATLPC0019952	Observation Plecanatide exhibits little to no binding to human serum albumin or human α-1-acid glycoprotein.	PepTherDia curated product PK fieldplasma proteinORAL	Reported	Open
12	Plasma protein binding Distribution / Barrier	ATLPC0011948	99 %	PepTherDia curated product PK fieldplasma proteinSC, ORAL	Comparable	Open
13	Plasma protein binding Distribution / Barrier	ATLPC0005195	99 %	PepTherDia curated product PK fieldplasma proteinSC	Comparable	Open
14	Plasma protein binding Distribution / Barrier	ATLPC0018293	43-49 %	PepTherDia curated product PK fieldplasma proteinSC, IM, TOPICAL	Comparable	Open
15	Plasma protein binding Distribution / Barrier	ATLPC0021413	80 %	PepTherDia curated product PK fieldplasma proteinNASAL	Comparable	Open
16	Plasma protein binding Distribution / Barrier	ATLPC0019426	86 %	PepTherDia curated product PK fieldplasma proteinSC	Comparable	Open
17	Plasma protein binding Distribution / Barrier	ATLPC0015970	50 %	PepTherDia curated product PK fieldplasma proteinIT	Comparable	Open
18	Plasma protein binding Distribution / Barrier	ATLPC0008117	97 %	PepTherDia curated product PK fieldplasma proteinIV	Comparable	Open
19	Plasma protein binding Distribution / Barrier	ATLPC0002483	85 %	PepTherDia curated product PK fieldplasma proteinIV	Comparable	Open
20	Plasma protein binding Distribution / Barrier	ATLPC0025660	21 %	PepTherDia curated product PK fieldplasma proteinSC	Comparable	Open

1–20 / 125

Measurements

Browse by ADMET domain

Evidence entries